ConductScience.org, home

Paper334223

Nomifensine in Parkinson's disease.

Bedard P and 2 others. Br J Clin Pharmacol, 1977. Cited by 28 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Nomifensine in Parkinson's disease. Papers, record 334223. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/334223

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nomifensine in Parkinson's disease.
PubMed
Journal
Br J Clin Pharmacol
PubMed
Year
1977
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
1.01
iCite
Revised in PubMed
2019-05-09
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bedard PP
2Parkes JDJ D
3Marsden CDC D

Source PubMed

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
IsoquinolinesMajor topic
NomifensineMajor topic
Parkinson DiseaseMajor topic
Adult
Aged
Carbidopa
Clinical Trials as Topic
Drug Therapy, Combination
Female
Humans
Levodopa
Male
Middle Aged
Placebos
Trihexyphenidyl

Source PubMed

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1796,415Nomifensine in parkinsonism.J Neurol Neurosurg Psychiatry1976https://conductscience.org/library/papers/796415PubMed
2778,880Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.Psychol Med1976https://conductscience.org/library/papers/778880PubMed
34,375,258Effect of nomifensine on motor activity, dopamine turnover rate and cyclic 3',5;-adenosine monophosphate concentrations of rat striatum.Naunyn Schmiedebergs Arch Pharmacol1974https://conductscience.org/library/papers/4375258PubMed
44,152,974Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum.J Pharm Pharmacol1974https://conductscience.org/library/papers/4152974PubMed
54,396,660Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain.Eur J Pharmacol1971https://conductscience.org/library/papers/4396660PubMed
64,147,437A study of the role of catecholamines in the response to various central stimulants.Eur J Pharmacol1973https://conductscience.org/library/papers/4147437PubMed
77,659The effects of blocking catecholamine uptake on amphetamine-induced circling behaviour in mice with unilateral destruction of striatal dopaminergic nerve terminals.J Pharm Pharmacol1976https://conductscience.org/library/papers/7659PubMed
84,441,422Effect of nomifensine (HOE 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomes.Biochem Pharmacol1974https://conductscience.org/library/papers/4441422PubMed
94,740,6958-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, a new antidepressant.Arzneimittelforschung1973https://conductscience.org/library/papers/4740695PubMed
101,097,600Amphetamines in the treatment of Parkinson's disease.J Neurol Neurosurg Psychiatry1975https://conductscience.org/library/papers/1097600PubMed
111,098,084Nomifensine: a potent dopaminergic agonist of antiparkinson potential.Psychopharmacologia1975https://conductscience.org/library/papers/1098084PubMed
12986,308Methylphenidate-like effects of the new antidepressant drug nomifensine (HOE 984).Eur J Pharmacol1976https://conductscience.org/library/papers/986308PubMed

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
33,824,605Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence.J Exp Pharmacol2021https://conductscience.org/library/papers/33824605PubMed
32,860,561The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.J Neural Transm (Vienna)2020https://conductscience.org/library/papers/32860561PubMed
25,810,948Monoamine reuptake inhibitors in Parkinson's disease.Parkinsons Dis2015https://conductscience.org/library/papers/25810948PubMed
22,233,519A searchable cross-platform gene expression database reveals connections between drug treatments and disease.BMC Genomics2012https://conductscience.org/library/papers/22233519PubMed
21,562,283Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.J Neurosci2011https://conductscience.org/library/papers/21562283PubMed
15,954,137Antidepressant studies in Parkinson's disease: a review and meta-analysis.Mov Disord2005https://conductscience.org/library/papers/15954137PubMed
9,467,687Depression in Parkinson's disease. Pharmacological characteristics and treatment.Drugs Aging1998https://conductscience.org/library/papers/9467687PubMed
911,653A profile of nomifensine.Br J Clin Pharmacol1977https://conductscience.org/library/papers/911653PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/334223

GET https://conductscience.org/api/papers/v1/334223/authors